322 related articles for article (PubMed ID: 26075833)
1. Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling.
Shida S; Utoh M; Murayama N; Shimizu M; Uno Y; Yamazaki H
Xenobiotica; 2015; 45(10):881-6. PubMed ID: 26075833
[TBL] [Abstract][Full Text] [Related]
2. Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation.
Koyanagi T; Nakanishi Y; Murayama N; Yamaura Y; Ikeda K; Yano K; Uehara S; Utoh M; Kim S; Uno Y; Yamazaki H
Xenobiotica; 2015 Apr; 45(4):312-21. PubMed ID: 25364857
[TBL] [Abstract][Full Text] [Related]
3. Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling.
Utoh M; Suemizu H; Mitsui M; Kawano M; Toda A; Uehara S; Uno Y; Shimizu M; Sasaki E; Yamazaki H
Xenobiotica; 2016 Dec; 46(12):1049-1055. PubMed ID: 26916082
[TBL] [Abstract][Full Text] [Related]
4. Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling.
Shida S; Yamazaki H
Xenobiotica; 2016 Sep; 46(9):759-64. PubMed ID: 26652678
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
Uehara S; Inoue T; Utoh M; Toda A; Shimizu M; Uno Y; Sasaki E; Yamazaki H
Xenobiotica; 2016; 46(2):163-8. PubMed ID: 26114209
[TBL] [Abstract][Full Text] [Related]
6. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Toda A; Uehara S; Inoue T; Utoh M; Kusama T; Shimizu M; Uno Y; Mogi M; Sasaki E; Yamazaki H
Xenobiotica; 2018 Jul; 48(7):720-726. PubMed ID: 28686070
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs.
Mogi M; Toda A; Iwasaki K; Kusumoto S; Takehara H; Shimizu M; Murayama N; Izumi H; Utoh M; Yamazaki H
J Toxicol Sci; 2012; 37(6):1157-64. PubMed ID: 23208431
[TBL] [Abstract][Full Text] [Related]
8. R-warfarin clearances from plasma associated with polymorphic cytochrome P450 2C19 and simulated by individual physiologically based pharmacokinetic models for 11 cynomolgus monkeys.
Utoh M; Kusama T; Miura T; Mitsui M; Kawano M; Hirano T; Shimizu M; Uno Y; Yamazaki H
Xenobiotica; 2018 Feb; 48(2):206-210. PubMed ID: 28136132
[TBL] [Abstract][Full Text] [Related]
9. Association with polymorphic marmoset cytochrome P450 2C19 of in vivo hepatic clearances of chirally separated R-omeprazole and S-warfarin using individual marmoset physiologically based pharmacokinetic models.
Kusama T; Toda A; Shimizu M; Uehara S; Inoue T; Uno Y; Utoh M; Sasaki E; Yamazaki H
Xenobiotica; 2018 Oct; 48(10):1072-1077. PubMed ID: 29034770
[TBL] [Abstract][Full Text] [Related]
10. Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models.
Utoh M; Miura T; Kusama T; Uehara S; Shimizu M; Uno Y; Yamazaki H
Biopharm Drug Dispos; 2017 Oct; 38(7):439-442. PubMed ID: 28608515
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
Uchida S; Tanaka S; Namiki N
Biopharm Drug Dispos; 2014 May; 35(4):228-36. PubMed ID: 24395703
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
13. Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo.
Utoh M; Yoshikawa T; Hayashi Y; Shimizu M; Iwasaki K; Uno Y; Yamazaki H
Biochem Pharmacol; 2015 May; 95(2):110-4. PubMed ID: 25801008
[TBL] [Abstract][Full Text] [Related]
14. Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
Machavaram KK; Endo-Tsukude C; Terao K; Gill KL; Hatley OJ; Gardner I; Parrott N; Ducray PS
AAPS J; 2019 Mar; 21(3):42. PubMed ID: 30887238
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
Zhuang Y; de Vries DE; Xu Z; Marciniak SJ; Chen D; Leon F; Davis HM; Zhou H
J Clin Pharmacol; 2015 Dec; 55(12):1386-94. PubMed ID: 26054042
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of drug-metabolizing cytochrome P450 enzymes in cynomolgus and rhesus monkeys and common marmosets in preclinical studies for humans.
Uno Y; Uehara S; Yamazaki H
Biochem Pharmacol; 2018 Jul; 153():184-195. PubMed ID: 29277691
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.
Bosilkovska M; Déglon J; Samer C; Walder B; Desmeules J; Staub C; Daali Y
Bioanalysis; 2014 Jan; 6(2):151-64. PubMed ID: 24423593
[TBL] [Abstract][Full Text] [Related]
18. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
19. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes.
Yoda N; Emoto C; Date S; Kondo S; Miyake M; Nakazato S; Umehara K; Kashiyama E
Xenobiotica; 2012 Aug; 42(8):719-30. PubMed ID: 22324396
[TBL] [Abstract][Full Text] [Related]
20. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
Drug Metab Pharmacokinet; 2011 Jun; 26(3):300-6. PubMed ID: 21383522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
